Rasagiline Ameliorates Olfactory Deficits in an Alpha- Synuclein Mouse Model of Parkinson’s Disease

Impaired olfaction is an early pre-motor symptom of Parkinson’s disease. The neuropathology underlying olfactory dysfunction in Parkinson’s disease is unknown, however a-synuclein accumulation/aggregation and altered neurogenesis might play a role. We characterized olfactory deficits in a transgenic mouse model of Parkinson’s disease expressing human wild-type a-synuclein under the control of the mouse a-synuclein promoter. Preliminary clinical observations suggest that rasagiline, a monoamine oxidase-B inhibitor, improves olfaction in Parkinson’s disease. We therefore examined whether rasagiline ameliorates olfactory deficits in this Parkinson’s disease model and investigated the role of olfactory bulb neurogenesis. a-Synuclein mice were progressively impaired in their ability to detect odors, to discriminate between odors, and exhibited alterations in short-term olfactory memory. Rasagiline treatment rescued odor detection and odor discrimination abilities. However, rasagiline did not affect short-term olfactory memory. Finally, olfactory changes were not coupled to alterations in olfactory bulb neurogenesis. We conclude that rasagiline reverses select olfactory deficits in a transgenic mouse model of Parkinson’s disease. The findings correlate with preliminary clinical observations suggesting tha